Page 1 of 1INSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form.Use additional sheet(s) if necessary.1. Company Name and Address4. EPA ProductRegistrationOMB Approval 2070-0107OMB Approval 2070-0057United States Environmental ProtectionAgency Washington, D.C. 20460DATA CALL-IN RESPONSE3. Date and Type of DCI and NumberGENERIC12-May-2010ID # GDCI-083301-297112. Case # and Name3074 Grotan (*)Chemical # and Name083301Hexahydro-1,3,5-tris(2-hydroxyethyl)-s-triazine5. I wish tocancel thisproduct registration voluntarily6. Generic Data7. Product Specific Data7a. My product is an MUP andI agree to satisfy the MUPrequirements on the attachedform entitled "RequirementsStatus and Registrant'sResponse."7b. My product is an EUP andI agree to satisfy the EUPrequirements on the attachedform entitled "RequirementsStatus and Registrant'sResponse."6a. I am claiming a GenericData Exemption because Iobtain the active ingredientfrom the source EPA registration number listed below.6b. I agree to satisfy GenericData requirements as indicatedon the attached form entitled"Requirements Status andRegistrant's Response."N.A.N.A.10. Name of Company11. Phone Number9. Date8. Certification I certify that the statements made on this form and all attachments are true, accurate, and complete. I acknowledge that anyknowingly false or misleading statement may be punishable by fine, imprisonment or both under applicable law.Signature and Title of Company's Authorized Representative__________________________________Hexahydro-1,3,5-tris(2-hydroxyethyl)-s-triazineINSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form.Use additional sheet(s) if necessary.4. GuidelineRequirementNumber5. Study Title1. Company Name and AddressPage 1 of 2OMB Approval 2070-0107OMB Approval 2070-0057United States Environmental ProtectionAgency Washington, D.C. 20460REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE3. Date and Type of DCI and NumberID #GENERIC12-May-2010GDCI-083301-297112. Case # and Name3074 Grotan (*)083301Chemical # and Name8. TimeFrame(Months)9. RegistrantResponse7. TestSubstance6. UsePatternPROTOCOLProgressReports321Applicator Exposure Data Requirements (Antimicrobial)(22 ,23 ,24)875.110024M, XDermal exposure--outdoor(25 ,26 ,27)875.120024M, XDermal exposure--Indoor(28 ,29 ,30)875.130024M, XInhalation exposure--outdoor(31 ,32 ,33,34)875.140024M, XInhalation exposure--indoor(35 ,40)875.160024M, XApplication exposure monitoring data reporting(38)875.170024M, XProduct Use InformationPost-Application Exposure Data Requirements (ConventionalChemical)(37)875.290024M, XData reporting and calculationsPostapplication Exposure Data Requirements (Antimicrobial)(36)875.280024M, XDescription of human activity(39)875.270024M, XProduct Use Information12. Name of Company13. Phone NumberSignature and Title of Company's Authorized Representative__________________________________10. Certification I certify that the statements made on this form and all attachments are true, accurate, and complete. Iacknowledge that anyknowingly false or misleading statement may be punishable by fine, imprisonment or both under applicable law11. DateHexahydro-1,3,5-tris(2-hydroxyethyl)-s-triazineINSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form.Use additional sheet(s) if necessary.4. GuidelineRequirementNumber5. Study Title1. Company Name and AddressPage 2 of 2OMB Approval 2070-0107OMB Approval 2070-0057United States Environmental ProtectionAgency Washington, D.C. 20460REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE3. Date and Type of DCI and NumberID #GENERIC12-May-2010GDCI-083301-297112. Case # and Name3074 Grotan (*)083301Chemical # and Name8. TimeFrame(Months)9. RegistrantResponse7. TestSubstance6. UsePatternPROTOCOLProgressReports321Toxicology Data Requirements (Antimicrobial)(1 ,2 ,3 ,4)870.13008MP; TGAI/MPM, XAcute inhalation toxicity(5 ,6 ,7)870.315024TGAIM, X90-day oral toxicity in nonrodents(8)870.346524TGAIM, X90-day inhalation toxicity(9 ,10 ,11)870.370024TGAIM, XPrenatal developmental toxicity study(12 ,13)870.380048TGAIM, XReproduction and fertility effects(14 ,15 ,16,17)870.410048TGAIM, XChronic toxicity(18 ,19 ,20,21)870.420048TGAIM, XCarcinogenicityInitial to indicate certification as to information on this page (fulltext of certification is on page one).DateCase # and Name:3074 Grotan (*)DCI Number:GDCI-083301-29711Page 1 of 4[The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Footnotes:Key:United States Environmental ProtectionAgency Washington, D.C. 20460FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTSMP; TGAI = Manufacturing Use Product; Technical Grade Active Ingredient; MP = Manufacturing Use Product [MP]; TGAI = TechnicalGrade Active Ingredient [TGAI]Use Categories Key:M -X -Indoor nonfood useMaterials preservatives1For the six acute studies conducted with the end-use product, the test must be conducted using the product as formulated for sale and distribution. If the product is intended and labeled to bediluted for use, the applicant may also wish to conduct certain studies using the highest diluted concentration (i.e. lowest dilution rate) permitted by the labeling.2Required when the product consists of, or under conditions of use will result in, an inhalable material (e.g., gas, vapor, aerosol or particulates).3The 870 series studies for the MP and EP are intended to provide data on the acute toxicity of the product. Waivers for any orall of these studies may be granted when the applicant candemonstrate that the combination of inert ingredients is not likely to pose any significant human health risks. Where appropriate, the limit dose approach to testing is recommended.4Required when the product consists of, or under conditions of use will result in, an inhalable material (e.g. gas, volatile substances, or aerosol particulate).5The 90-day dermal toxicity study or 90-day inhalation toxicity study may be substituted for the 90-day oral toxicity study if it is determined that dermal or inhalation exposure is a major route ofexposure.6The 90-day oral toxicity test in nonrodents may be required when the use of the antimicrobial pesticide is likely to result inrepeated human exposure over a considerable portion of the humanlifespan, as determined by the Agency, or when the use requires a tolerance or exemption from the requirement for a tolerance.7This test is required for low-exposure indirect food uses.8Required if the active ingredient is a gas at room temperature or if the Agency determines that use of the product may result in repeated inhalation exposure at a concentration likely to be toxicregardless of whether the major route of exposure is inhalation.9The test substance must be administered orally or by gastric intubation.10The test substance must be administered orally or by gastric intubation.11When a pesticide is determined to be a developmental toxicant after oral dosing and dermal exposure is determined by the Agencyto be significant, additional testing via the dermal route maybe required to determine whether the pesticide poses a risk of developmental toxicity through dermal exposure.12Atwo-generation reproduction study is required.13Required for low exposure uses if use of the antimicrobial pesticide product is likely to result in significant human exposure,as determined by the Agency, in terms of the frequency, magnitude,or duration of the exposure.14The 90-day oral toxicity test in nonrodents may be required when the use of the antimicrobial pesticide is likely to result inrepeated human exposure over a considerable portion of the humanlifespan, as determined by the Agency, or when the use requires a tolerance or exemption from the requirement for a tolerance.15The 90-day oral toxicity test in nonrodents may be required when the use of the antimicrobial pesticide is likely to result inrepeated human exposure over a considerable portion of the humanlifespan, as determined by the Agency, or when the use requires a tolerance or exemption from the requirement for a tolerance.Case # and Name:3074 Grotan (*)DCI Number:GDCI-083301-29711Page 2 of 4[The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Footnotes:Key:United States Environmental ProtectionAgency Washington, D.C. 20460FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTSMP; TGAI = Manufacturing Use Product; Technical Grade Active Ingredient; MP = Manufacturing Use Product [MP]; TGAI = TechnicalGrade Active Ingredient [TGAI]16Studies which are designed to simultaneously fulfill the requirements of both the chronic oral and carcinogenicity studies (i.e. a combined study under Guideline 870.4300) may be conducted.17Studies which are designed to simultaneously fulfill the requirements of both the chronic oral and carcinogenicity studies (i.e. a combined study under Guideline 870.4300) may be conducted.18If the requirement for a carcinogenicity study in any species is modified or waived for any reason, then a subchronic 90-day oral study in the same species, conducted in accordance withGuideline 870.3100, may be required to evaluate potential to produce preneoplastic lesions.19If the requirement for a carcinogenicity study in any species is modified or waived for any reason, then a subchronic 90-day oral study in the same species, conducted in accordance withGuideline 870.3100, may be required to evaluate potential to produce preneoplastic lesions.20For low exposure antimicrobials, a carcinogenicity study in two species is required if any of the following criteria are met:(i) The weight of evidence indicates carcinogenic potential of the activeingredient or any of its metabolites, transformation products or impurities based upon consideration of whether the substance:(A) Is structurally related to a recognized carcinogen. (B) Causesmutagenic effects as demonstrated by in vitro or in vivo testing. (C) Produces a morphologic effect in any organ (e.g., hyperplasia, metaplasia) in subchronic studies that may lead to neoplasticchange. (ii) Use of the pesticide product is likely to result inhuman exposure over a substantial portion of the human life span which is significant in terms of the frequency, magnitude, orduration of exposure.21For low exposure antimicrobials, a carcinogenicity study in two species is required if any of the following criteria are met:(i) The weight of evidence indicates carcinogenic potential of the activeingredient or any of its metabolites, transformation products or impurities based upon consideration of whether the substance:(A) Is structurally related to a recognized carcinogen. (B) Causesmutagenic effects as demonstrated by in vitro or in vivo testing. (C) Produces a morphologic effect in any organ (e.g., hyperplasia, metaplasia) in subchronic studies that may lead to neoplasticchange. (ii) Use of the pesticide product is likely to result inhuman exposure over a substantial portion of the human life span which is significant in terms of the frequency, magnitude, orduration of exposure.22The Agency will require application exposure data beyond the required product use information (Guideline 875.1700) if at leastone of the following exposure criteria and at least one of thefollowing toxicity criteria are met by the TEP, TGAI, or one of the pesticide's metabolites: (i) Exposure criteria. (A) Dermalexposure is likely to occur during use. (B) Inhalation exposure is likelyto occur during use. (C) Adequate surrogate exposure data (e.g. PHED) to estimate the magnitude of exposure for a particular work activity with an acceptable degree of confidence areunavailable. (ii) Toxicity criteria. (A) The acute dermal LD50 is less than or equal to 200 mg/kg (i.e., Toxicity CategoryI (Guideline 870.1200) as per 40 CFR 156.10). (B) The acute inhalationLC50 (Guideline 870.1300) is less than or equal to 0.05 mg/liter (i.e., 4-hour exposure, Toxicity Category I) and the TGAI hasa vapor pressure greater than 10-3 mm Hg at 25degrees C if usedoutdoors or any indoor application regardless of the vapor pressure. (C) The pesticide is found to be a neurotoxicant (Guideline 870.6200). (D) The pesticide is found to be a developmentaltoxicant (Guidelines 870.3700 and 870.6300). (E) The pesticide is found to be a carcinogen (Guideline 870.4200). (F) The pesticide shows potential adverse effects in subchronic studies suchas 90-day oral (Guideline 870.3100), 21-day repeated dermal toxicity (Guideline 870.3200), 90-day dermal toxicity (Guideline 870.3250), 90-day inhalation (Guideline 870.3465), reproductionand fertility effects (Guideline 870.3800), and chronic feeding (Guideline 870.4100). (G) The pesticide is found to be a mutagen (Guidelines 870.5100 to 870.5900) or an immunotoxicant(Guideline 870.7800). (H) Epidemiological or poisoning incidence data indicate adverse effects from handling the pesticide.23Required for outdoor uses when that is the primary use or if outdoor uses are expected to result in greater exposure than indoor uses.24Protocols must be submitted to the Agency for approval before initiating a study.Case # and Name:3074 Grotan (*)DCI Number:GDCI-083301-29711Page 3 of 4[The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Footnotes:Key:United States Environmental ProtectionAgency Washington, D.C. 20460FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTSMP; TGAI = Manufacturing Use Product; Technical Grade Active Ingredient; MP = Manufacturing Use Product [MP]; TGAI = TechnicalGrade Active Ingredient [TGAI]25The Agency will require application exposure data beyond the required product use information (Guideline 875.1700) if at leastone of the following exposure criteria and at least one of thefollowing toxicity criteria are met by the TEP, TGAI, or one of the pesticide's metabolites: (i) Exposure criteria. (A) Dermalexposure is likely to occur during use. (B) Inhalation exposure is likelyto occur during use. (C) Adequate surrogate exposure data (e.g. PHED) to estimate the magnitude of exposure for a particular work activity with an acceptable degree of confidence areunavailable. (ii) Toxicity criteria. (A) The acute dermal LD50 is less than or equal to 200 mg/kg (i.e., Toxicity CategoryI (Guideline 870.1200) as per 40 CFR 156.10). (B) The acute inhalationLC50 (Guideline 870.1300) is less than or equal to 0.05 mg/liter (i.e., 4-hour exposure, Toxicity Category I) and the TGAI hasa vapor pressure greater than 10-3 mm Hg at 25degrees C if usedoutdoors or any indoor application regardless of the vapor pressure. (C) The pesticide is found to be a neurotoxicant (Guideline 870.6200). (D) The pesticide is found to be a developmentaltoxicant (Guidelines 870.3700 and 870.6300). (E) The pesticide is found to be a carcinogen (Guideline 870.4200). (F) The pesticide shows potential adverse effects in subchronic studies suchas 90-day oral (Guideline 870.3100), 21-day repeated dermal toxicity (Guideline 870.3200), 90-day dermal toxicity (Guideline 870.3250), 90-day inhalation (Guideline 870.3465), reproductionand fertility effects (Guideline 870.3800), and chronic feeding (Guideline 870.4100). (G) The pesticide is found to be a mutagen (Guidelines 870.5100 to 870.5900) or an immunotoxicant(Guideline 870.7800). (H) Epidemiological or poisoning incidence data indicate adverse effects from handling the pesticide.26Protocols must be submitted to the Agency for approval before initiating a study.27Required for indoor uses such as aquaria when the Agency determines such uses are likely to result in greater exposure than outdoor uses.28The Agency will require application exposure data beyond the required product use information (Guideline 875.1700) if at leastone of the following exposure criteria and at least one of thefollowing toxicity criteria are met by the TEP, TGAI, or one of the pesticide's metabolites: (i) Exposure criteria. (A) Dermalexposure is likely to occur during use. (B) Inhalation exposure is likelyto occur during use. (C) Adequate surrogate exposure data (e.g. PHED) to estimate the magnitude of exposure for a particular work activity with an acceptable degree of confidence areunavailable. (ii) Toxicity criteria. (A) The acute dermal LD50 is less than or equal to 200 mg/kg (i.e., Toxicity CategoryI (Guideline 870.1200) as per 40 CFR 156.10). (B) The acute inhalationLC50 (Guideline 870.1300) is less than or equal to 0.05 mg/liter (i.e., 4-hour exposure, Toxicity Category I) and the TGAI hasa vapor pressure greater than 10-3 mm Hg at 25degrees C if usedoutdoors or any indoor application regardless of the vapor pressure. (C) The pesticide is found to be a neurotoxicant (Guideline 870.6200). (D) The pesticide is found to be a developmentaltoxicant (Guidelines 870.3700 and 870.6300). (E) The pesticide is found to be a carcinogen (Guideline 870.4200). (F) The pesticide shows potential adverse effects in subchronic studies suchas 90-day oral (Guideline 870.3100), 21-day repeated dermal toxicity (Guideline 870.3200), 90-day dermal toxicity (Guideline 870.3250), 90-day inhalation (Guideline 870.3465), reproductionand fertility effects (Guideline 870.3800), and chronic feeding (Guideline 870.4100). (G) The pesticide is found to be a mutagen (Guidelines 870.5100 to 870.5900) or an immunotoxicant(Guideline 870.7800). (H) Epidemiological or poisoning incidence data indicate adverse effects from handling the pesticide.29Required for outdoor uses when that is the primary use or if outdoor uses are expected to result in greater exposure than indoor uses.30Protocols must be submitted to the Agency for approval before initiating a study.Case # and Name:3074 Grotan (*)DCI Number:GDCI-083301-29711Page 4 of 4[The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Footnotes:Key:United States Environmental ProtectionAgency Washington, D.C. 20460FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTSMP; TGAI = Manufacturing Use Product; Technical Grade Active Ingredient; MP = Manufacturing Use Product [MP]; TGAI = TechnicalGrade Active Ingredient [TGAI]Use Categories Key:M -X -Indoor nonfood useMaterials preservatives31The Agency will require application exposure data beyond the required product use information (Guideline 875.1700) if at leastone of the following exposure criteria and at least one of thefollowing toxicity criteria are met by the TEP, TGAI, or one of the pesticide's metabolites: (i) Exposure criteria. (A) Dermalexposure is likely to occur during use. (B) Inhalation exposure is likelyto occur during use. (C) Adequate surrogate exposure data (e.g. PHED) to estimate the magnitude of exposure for a particular work activity with an acceptable degree of confidence areunavailable. (ii) Toxicity criteria. (A) The acute dermal LD50 is less than or equal to 200 mg/kg (i.e., Toxicity CategoryI (Guideline 870.1200) as per 40 CFR 156.10). (B) The acute inhalationLC50 (Guideline 870.1300) is less than or equal to 0.05 mg/liter (i.e., 4-hour exposure, Toxicity Category I) and the TGAI hasa vapor pressure greater than 10-3 mm Hg at 25degrees C if usedoutdoors or any indoor application regardless of the vapor pressure. (C) The pesticide is found to be a neurotoxicant (Guideline 870.6200). (D) The pesticide is found to be a developmentaltoxicant (Guidelines 870.3700 and 870.6300). (E) The pesticide is found to be a carcinogen (Guideline 870.4200). (F) The pesticide shows potential adverse effects in subchronic studies suchas 90-day oral (Guideline 870.3100), 21-day repeated dermal toxicity (Guideline 870.3200), 90-day dermal toxicity (Guideline 870.3250), 90-day inhalation (Guideline 870.3465), reproductionand fertility effects (Guideline 870.3800), and chronic feeding (Guideline 870.4100). (G) The pesticide is found to be a mutagen (Guidelines 870.5100 to 870.5900) or an immunotoxicant(Guideline 870.7800). (H) Epidemiological or poisoning incidence data indicate adverse effects from handling the pesticide.32Required for outdoor uses when that is the primary use or if outdoor uses are expected to result in greater exposure than indoor uses.33Protocols must be submitted to the Agency for approval before initiating a study.34Required for indoor uses such as aquaria when the Agency determines such uses are likely to result in greater exposure than outdoor uses.35Data reporting and calculations are required when exposure data are submitted.36The required description of human activity data include data such as frequency and duration of exposure to evaluate the potential differences in exposures of different subpopulations (e.g. adultsand children), and to determine how specific postapplication activity patterns affect exposure levels.37Data reporting and calculations are required when exposure data are submitted.38Use information pertains to the methods of mixing, loading and applying the pesticide and associated work practices that will play an integral part in determining exposure to antimicrobialpesticide handlers. Required product use information includes range and typical values for: Application rates; area treated per day and per year; timing and number of treatments per day andper year for private and professional handlers; exposure time per activity; types of handling equipment; type of clothing worn;geographical distribution of use; and other relevant use data.39Required product use information includes reapplication rates and frequencies, re-entry intervals, rinsing and other residue removal practices, and any other use data relevant to exposure afterapplication.40Data are required for both dermal and inhalation exposure.United States Environmental ProtectionAgency Washington, D.C. 20460LIST OF ALL REGISTRANTS SENT THIS DATA CALL-IN NOTICECo. Nr.Company NameAgent ForAddressCity & StateZipCase # and Name:3074,Grotan (*)TROY CHEMICAL COMPANYLIMITEDLEWIS & HARRISON122 C ST NW STE 740WASHINGTONDC20001365INTERNATIONAL SPECIALTYPRODUCTS1361 ALPS RD.WAYNENJ074701529STEPAN COMPANY22 W. FRONTAGE RD.NORTHFIELDIL600931839BASF CORPORATION100 CAMPUS DRIVEFLORHAM PARKNJ0793233753ARCH CHEMICALS, INC.5660 NEW NORTHSIDE DRIVE, N.W., SUITE 1100ATLANTAGA303281258